| Catalog No | Package | Original Price | Price | Inventory | Quantity | Operating |
|---|---|---|---|---|---|---|
| BP0620-5mg | 5mg | $420.00 | Sign in |
|
Product name: Ganoderic Acid H
Synonym name: Ganoderic acid C
Catalogue No.: BP0620
Cas No.: 98665-19-1
Formula: C32H44O9
Mol Weight: 572.695
Botanical Source: From Ganoderma lucidum (reishi)
Physical Description: Powder
Type of Compound: Triterpenoids
Purity: 95%~99%
Analysis Method: HPLC-DAD or/and HPLC-ELSD
Identification Method: Mass, NMR
Packing: Brown vial or HDPE plastic bottle
Storage: Store in a well closed container, protected from air and light. Put into refrigerate or freeze for long term storage.
Whenever possible, you should prepare and use solutions on the same day. However, if you need to make up stock solutions in advance, we recommend that you store the solution as aliquots in tightly sealed vials at -20℃. Generally, these will be useable for up to two weeks.
The product could be supplied from milligrams to grams, up to kilograms
Inquire for bulk scale.
Descriptions:
Ganoderic acid H( GA-H )and ganoderic acid A(GA-A ) suppress growth (cell proliferation and colony formation) and invasive behavior (adhesion, migration and invasion) of MDA-MB-231 cells; they mediate their biological effects through the inhibition of transcription factors AP-1 and NF-kappaB, resulting in the down-regulation of expression of Cdk4 and the suppression of secretion of uPA, respectively; furthermore, the activity of ganoderic acids is linked to the hydroxylation in the position 7 and 15 (GA-A) and 3 (GA-H) in their triterpene lanostane structure; so hydroxylated triterpenes from G. lucidum could be promising natural agents for the therapy of invasive breast cancers.[1]
References:
[1] Jiang J, Grieb B, Thyagarajan A, et al. Int J Mol Med, 2008, 21(5):577-84.
[2] Wang X M, Guan S H, Liu R X, et al. Journal of Shenyang Pharmaceutical University, 2007, 24(07):407-9.
Storage conditions：Short-term storage at 2~8℃, long-term storage at -20 ~ -80℃
Ganoderma lucidum, as a traditional Chinese medicinal herb, has long been praised as the "grass of immortals" due to its broad pharmacological activity and significant health benefits. Among them, Ganoderic Acid H (Ganoderic Acid H), an important lanolin-type triterpenoid compound in Ganoderma, has attracted attention in recent years due to its multi-target and multi-mechanism biological activity. Ganodermic acid H not only exhibits remarkable anti-tumor activity, especially in inhibiting the growth and invading ability of breast cancer cells, but also possesses multiple biological functions such as immune regulation. This paper will systematically review the chemical structure and physicochemical properties of Ganodermic acid H, plant origin and extraction methods, pharmacological activity and mechanism of action, druggability evaluation, and pharmacokinetic characteristics, and explore its clinical application prospects and future research directions, aiming to provide theoretical basis and practical guidance for drug development of this natural product.
Ganodermal acid H (CAS No.: 98665-19-1) belongs to the lanolin-type triterpene compound, with a molecular formula of C_30H_48O_7 and a molecular weight of 572.6950. Its structural core is the pentacyclic lanolin alkane backbone, which contains multiple hydroxyl and carboxyl functional groups, giving it high polarity and biological activity. In terms of physicochemical properties, the LogP value of Ganoderma acid H is 2.8683, indicating moderate lipid solubility that facilitates cell membrane penetration, but its water solubility is relatively low (0.0152), which may limit its dispersibility and bioavailability in aqueous environments. Its topological pole surface area (TPSA) is 152.1100, indicating strong polarity and hydrogen bond formation capability, which is significant for its binding to biological macromolecule targets. Ganoderma acid H does not have blood-brain barrier penetration ability; hERG channel inhibition test was negative, and Ames' mutagenicity test result was zero, indicating high safety and low risk of toxic side effects.
Ganoderma acid H mainly comes from the fruiting body and mycelium of Ganoderma. Ganoderma is a fungus of the genus Ganoderma in the Polypore family, widely distributed in temperate and subtropical regions of Asia. The content of triterpenes is significantly influenced by variety, cultivation environment, harvest time, and processing technology. Ganoderma acid H is usually extracted using organic solvents, with commonly used solvents including ethanol, methanol, and ethyl acetate. The extraction process generally includes steps such as drying and crushing, solvent extraction extraction, concentration, and separation and purification. In recent years, supercritical CO_2 extraction and ultrasound-assisted extraction techniques have gradually been applied to the extraction process of Ganoderma acid H to improve extraction efficiency and purity. In terms of purification, methods such as silica gel column chromatography and reversed-phase high-performance liquid chromatography (RP-HPLC) are commonly used to ensure the acquisition of high-purity Ganoderic acid H samples for pharmacological research.
The pharmacological activity of Ganodermic acid H mainly focuses on antitumor and immunomodulatory aspects. Numerous in vitro cell experiments have shown that Ganodermic acid H can significantly inhibit the proliferation and migration of breast cancer cells, induce apoptosis, and block the cell cycle process. In addition, Ganodermic acid H has regulatory effects on various immune-related targets, promoting the recovery and balance of the body's immune function.
Ganodermic acid H regulates multiple signaling pathways to inhibit the growth and invasion of tumor cells. Especially in breast cancer models, Ganodermic acid H exhibits significant cytotoxicity, reducing tumor cell proliferation and invasion and migration capabilities. Its antitumor mechanism involves inhibition of transcription factors AP-1 and NF-κB, thereby downregulating the expression of tumor-promoting genes and blocking the transmission of intracellular growth-promoting signals.
Ganodermic acid H has multiple regulatory effects on the immune system, regulating key immune-related targets such as TLR4, STAT3, IL2, NFKB1, TGFB1, CTLA4, STAT4, IL10, FOXP3, and IFNG, thereby modulating immune cell activity and cytokine secretion, thereby promoting immune balance. Its immunomodulatory effects help enhance the body's resistance to disease, suppress tumor immune escape, and improve inflammatory responses.
The mechanism of action of Ganodermic acid H mainly regulates intracellular signal transduction networks and transcription factor activity.
AP-1 and NF-κB are important transcription factors regulating cell proliferation, differentiation, apoptosis, and immune responses. Ganodermic acid H can inhibit the activation of these two signaling pathways, reducing the expression of pro-inflammatory cytokines and tumor genes, thereby inhibiting tumor cell growth and invasion. Specific mechanisms include blocking phosphorylation and degradation of IκBα, inhibiting nuclear translocation of the p65 subunit, and reducing the DNA-binding activity of the AP-1 complex.
The druggability evaluation of Ganodermic acid H indicates that it has certain potential for drug development. Although the molecular weight of 572.6950 is slightly above the ideal range for small molecule drugs, it is within a reasonable range among natural products. A LogP value of 2.8683 indicates moderate lipid solubility, which is beneficial for cell membrane penetration. A higher TPSA (152.1100) suggests strong polarity, which may affect oral absorption and bioavailability. Low water solubility (0.0152) is a major challenge in formulation development, requiring formulation improvements or nanocarrier technology to enhance solubility and bioavailability.
Low blood-brain barrier penetration suggests that Ganodermic acid H mainly acts on peripheral tissues, reducing the risk of central nervous system toxicity. The hERG channel inhibition test was negative, indicating a low risk of cardiotoxicity. The Ames test result was 0, indicating no mutagenicity and good safety.
Currently, pharmacokinetic research on Ganodermic acid H is relatively limited. Preliminary data indicate that it is absorbed orally slowly, widely distributed in the body, metabolized mainly through hepatic enzymes, and its excretion pathway requires further study. In the future, in vivo kinetic, metabolic pathway, and toxicological evaluation should be strengthened to lay the foundation for clinical development.
Ganodermic acid H, due to its significant antitumor and immunomodulatory effects, has broad clinical application prospects. As a common malignant tumor among women worldwide, breast cancer currently faces issues of drug resistance and side effects. Ganodermic acid H, as a natural product, offers a new therapeutic approach. Through multi-target and multi-mechanism synergistic effects, it can effectively inhibit tumor cell proliferation and metastasis, while regulating the immune status of the tumor microenvironment and enhancing anti-tumor immune responses, offering potential adjunctive therapeutic value.
In addition, Ganodermic acid H also shows good regulatory potential in immune-related diseases such as autoimmune diseases, chronic inflammation, and immune deficiency. In the future, modern drug delivery systems, such as nanocarriers and liposomes, can be combined to improve their pharmacokinetic properties, enhancing in vivo stability and targeting.
Preclinical research should further expand the spectrum of action of Ganoderma acid H, systematically evaluate its safety and effective dosage, conduct animal models and early clinical trials, and verify its efficacy and safety. By combining molecular docking and structural optimization, develop Ganodermic acid H derivatives or analogs to enhance their efficacy and druggability, and promote their clinical translation.
As an important triterpene natural product in Ganoderma lucidum, Ganodermic acid H shows broad application prospects in anti-tumor and immune regulation fields due to its unique chemical structure and multi-target pharmacological activity. By inhibiting the AP-1 and NF-κB signaling pathways, it regulates multiple immune-related targets, exerting synergistic anti-cancer and immunomodulatory effects. Although its water solubility and pharmacokinetic properties have certain limitations, modern drug development technologies and in-depth mechanistic studies are expected to overcome these obstacles and achieve clinical application. In the future, systematic research and clinical development of Ganodermic acid H will provide important examples for innovation in natural product drugs, promoting the modernization of traditional Chinese medicine and the advancement of precision therapy.
